There has been a lot of debate recently around pharma and its pursuit of multi-channel or omni-channel marketing ... more than standard monitors and insulin pumps did when tested for five days ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Embecta reports fourth quarter earnings beating estimates, discontinues insulin patch program, and announces restructuring ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our portfolio ...

These devices range from blood glucose meters and continuous glucose monitoring systems to insulin pumps, insulin pens, and other related accessories. It is important to note that the market does ...

These devices range from blood glucose meters and continuous glucose monitoring systems to insulin pumps, insulin pens, and other related accessories. It is important to note that the market does ...